These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12437648)

  • 1. Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis.
    Wang JC; Novetsky A; Chen C; Novetsky AD
    Br J Haematol; 2002 Dec; 119(3):709-12. PubMed ID: 12437648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia.
    Wang JC
    Leuk Lymphoma; 2005 Sep; 46(9):1261-8. PubMed ID: 16109602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ; Thiele J
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ
    Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data.
    Thiele J; Zankovich R; Steinberg T; Kremer B; Fischer R; Diehl V
    Acta Haematol; 1989; 81(4):192-202. PubMed ID: 2474228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease.
    Rosemar A; Ivarsson ML; Börjesson L; Holmdahl L
    Scand J Gastroenterol; 2007 Feb; 42(2):215-20. PubMed ID: 17327941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balance between matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) in the cervical mucus plug estimated by determination of free non-complexed TIMP.
    Becher N; Hein M; Uldbjerg N; Danielsen CC
    Reprod Biol Endocrinol; 2008 Sep; 6():45. PubMed ID: 18826601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.
    Gowin K; Coakley M; Kosiorek H; Mesa R
    Haematologica; 2016 Oct; 101(10):e405-e406. PubMed ID: 27354022
    [No Abstract]   [Full Text] [Related]  

  • 12. Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures.
    Marquez-Curtis LA; Dobrowsky A; Montaño J; Turner AR; Ratajczak J; Ratajczak MZ; Janowska-Wieczorek A
    Br J Haematol; 2001 Dec; 115(3):595-604. PubMed ID: 11736941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations Between MMPs and TIMPs Levels in Aqueous Humor from High Myopia and Cataract Patients.
    Jia Y; Hu DN; Sun J; Zhou J
    Curr Eye Res; 2017 Apr; 42(4):600-603. PubMed ID: 28402202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
    Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
    Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis.
    Montagnana M; Volpe A; Lippi G; Caramaschi P; Salvagno GL; Biasi D; Bambara LM; Guidi GC
    Clin Biochem; 2007 Aug; 40(12):837-42. PubMed ID: 17493602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.
    Latronico T; Mascia C; Pati I; Zuccala P; Mengoni F; Marocco R; Tieghi T; Belvisi V; Lichtner M; Vullo V; Mastroianni CM; Liuzzi GM
    Int J Mol Sci; 2016 Mar; 17(4):455. PubMed ID: 27023536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors.
    Fondard O; Detaint D; Iung B; Choqueux C; Adle-Biassette H; Jarraya M; Hvass U; Couetil JP; Henin D; Michel JB; Vahanian A; Jacob MP
    Eur Heart J; 2005 Jul; 26(13):1333-41. PubMed ID: 15827062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.